32 results about "Chikungunya" patented technology

The invention provides a bacillus thuringiensis strain, a fermentation culture method and application of the bacillus thuringiensis strain. The strain is preserved in the China Center for Type Culture Collection on September 28, 2011, the preservation address is No. 299 on eight road, Wuchang District, Wuhan City, Hubei Province, the preservation number is CCTCC No: M 2011334, and the preservation date is September 28, 2011. The strain cultured by the fermentation method has efficient, specific and stable insecticidal activity on culex, aedes and other mosquitoes, has the advantages of low preparation cost, environmental friendliness and the like, can be developed into a biological insecticide for preventing and killing mosquitoes and preventing and controlling malaria, dengue fever, chikungunya and other mosquito-borne infectious diseases, and meets the requirements of green and safe prevention and control in China.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application thereof, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention belongs to the technical field of biological detection, and relates to a Chikungunya virus detection kit and a detection method. The kit is based on the principle of PCR detection and comprises a primer pair, the sequence of a forward primer of the primer pair is shown as SEQ ID NO: 1, and the sequence of a reverse primer of the primer pair is shown as SEQ ID NO: 2. The chikungunya virus detection kit and the detection method can realize rapid, sensitive and specific detection of chikungunya virus based on the principle of PCR detection, and are especially suitable for various application scenes such as clinical samples, human or animal samples, environmental samples, scientific research samples and the like.

This invention discloses a chikungunya virus genome fragment armored RNA reference, its preparation method, and its application. The preparation process involves the following steps: (1) constructing the prokaryotic expression backbone vector pACYCAR; (2) cloning the CKV genome fragment CKA (nt17-2276); (3) constructing the prokaryotic expression vector pACYCAR-CKA; (4) inducing the expression of armored RNA; and (5) purifying the armored RNA. This invention solves the technical problems of high biosafety risk, poor stability, and insufficient gene fragment coverage in existing CKV nucleic acid detection references. It fills the gap in the lack of high-quality references for CKV detection.

The present disclosure provides neutralising human antibodies that binds to an alphavirus. The antibodies are raised against the chikungunya (CHIKV) virus, and show cross-neutralisation and in vivo protection of other alphaviruses.

The invention discloses a Chikungunya thermal seasonal propagation risk assessment method and system based on a coupling model. The method comprises the following steps: acquiring basic data and preprocessing the basic data; model parameters are divided into a fixed type and a dynamic type, the dynamic parameters are combined with environmental data to calculate and assign values, historical epidemic situation data in the past three years are used as target values, key parameters are adjusted through a least square method, and the error between a model simulation epidemic situation curve and an actual observation value is minimized. Based on the influence of a standardized meteorological data quantification environment on mosquitoes, generating a day-by-day key parameter sequence and inputting the day-by-day key parameter sequence into a medium module; the age structure model is used for simulating population dynamics of mosquitoes at all stages, and the SEI model is used for simulating transmission of viruses in the mosquitoes. The number of infectious mosquitoes output by the medium module is used as a drive, crowd state conversion is simulated through an SEIR model, and the number of infected people every day and the morbidity are obtained; and risk level assessment of the assessment area is completed, and quantitative data support is provided for risk assessment.

This application relates to the field of biomedical detection technology, specifically to a combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients and its application. The combination of biomarkers for assessing the severity of viremia in Chikungunya virus patients includes one or more of the following biomarkers: TAP1, ISG15, CMPK2, GBP4, OTOF, and SIGLEC1. The biomarker combination provided in this application can objectively and quantitatively reflect the activity of viral replication and the strength of the immune response in the patient, thereby achieving accurate assessment of the severity of viremia. This solves the problem in existing technologies that mainly rely on qualitative or semi-quantitative detection of viral nucleic acids and lack assessment methods closely related to the host's pathological state.

This invention discloses an attenuated chikungunya virus expressing a nanoluciferase gene, the nucleotide sequence of which is shown in SEQ ID NO:1. It is constructed by attenuating the virulence of the chikungunya virus LR2006-OPY1 strain by deleting 61 amino acids from positions 323 to 383 of the nsP3 protein and inserting a nanoluciferase gene after position 490 of the nsP3 protein. This virus model maintains similar growth characteristics to the wild-type virus but with significantly improved safety. Viral replication can be monitored in real time by detecting luciferase activity, making it suitable for drug screening at both cellular and animal levels. This provides an efficient and safe technical platform for the development of antiviral drugs against chikungunya virus.

The invention belongs to the field of gene engineering, and particularly relates to application of chikungunya virus structural protein in improvement of pseudovirus stability, a construction method of the chikungunya virus structural protein and vaccines, antibody evaluation and in-vivo gene therapy products. The method comprises the following steps: constructing a human codon optimized Asian strain CHIKV-E3 + E2 + 6K + E1 structural protein eukaryotic vector, and designing two types of binder expression plasmids of targeted T cells; the vector, a psPAX2 helper plasmid and a lentivirus target vector containing an SFFV promoter and a ZsGreen reporter gene (or a CAR therapeutic gene) are co-transformed into a 293T cell, and the lentivirus is prepared through culture, filtration and centrifugation. The lentivirus can efficiently infect Jurkat cells and activate human T cells, obviously reduces the infection efficiency on 293T cells so as to reduce the off-target effect, has excellent stability in human serum, and provides a safe and efficient gene delivery tool for in-vivo CAR-T therapy.

The invention discloses a chikungunya virus monoclonal antibody and application thereof in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The present invention relates to compounds for use in the treatment of a disease or condition caused by Zika virus, Dengue virus, West Nile virus, Chikungunya virus, O`nyong`nyong virus, Sindbis virus or SARS-CoV-2 virus.

The application discloses a multiplex qPCR primer probe set, a kit, a detection method and application for detecting alphaviruses, and belongs to the technical field of molecular biological detection. The application designs a set of primer probe combination for a plurality of alphaviruses capable of infecting insect cell lines, including western equine encephalitis virus, eastern equine encephalitis virus, sindbis virus, chikungunya virus, AURA virus and Venezuelan equine encephalitis virus. The combination realizes synchronous detection and identification of a plurality of target viruses in one reaction system. The application also provides a kit containing the primer probe set and a corresponding detection method. The detection method has the advantages of wide coverage, high detection sensitivity, strong specificity, good anti-matrix interference capability and the like, and is suitable for safety detection and quality control of alphavirus contamination in insect cell banks, cell cultures and related biological products.

This invention belongs to the fields of molecular virology and immunology, and provides an alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its applications. The nanobody has a heavy chain variable region (VHH), which comprises the following CDRs: CDR1 (amino acid sequence as shown in SEQ ID NO:1), CDR2 (amino acid sequence as shown in SEQ ID NO:2), and CDR3 (amino acid sequence as shown in SEQ ID NO:3). The VHH includes four frame regions FR1-FR4; FR1, FR2, FR3, and FR4 are arranged alternately with CDR1, CDR2, and CDR3 in sequence. The nanobody of this invention can efficiently neutralize CHIKV virus and inhibit its infection, and has the potential to prepare drugs or kits for the prevention, treatment, and / or detection of CHIKV infection. The nanobody of this invention can bind with high affinity to the E protein of CHIKV, effectively inhibiting CHIKV pseudovirus infection.

The application discloses a carbon-coated zirconium oxide composite material, a colorimetric / photothermal dual-mode signal nano probe and application thereof in rapid quantitative detection of chikungunya virus. The colorimetric / photothermal dual-mode signal nano probe is formed by coupling a carbon-coated zirconium oxide composite nano material obtained by calcining mesoporous UiO-66 in an inert atmosphere with a chikungunya virus E2 protein monoclonal antibody. In a specific application, a chromatography test strip is constructed based on the colorimetric / photothermal dual-mode signal nano probe. The chromatography test strip comprises a nitrocellulose membrane provided with a T line and a C line. During detection, a sample and the nano probe form an immune complex and generate a colorimetric signal visible to the naked eye at the T line, and meanwhile, under the irradiation of 808 nm near-infrared laser, a temperature rise Delta T related to the concentration of a target object is generated at the T line, so that on-site rapid screening and photothermal quantitative review are realized. The chromatography test strip has both simple operation and reliable quantification, and has stronger anti-interference ability in a complex biological matrix, and is suitable for instant detection of chikungunya virus.

The invention discloses a chikungunya virus envelope E2 protein monoclonal antibody and application of the chikungunya virus envelope E2 protein monoclonal antibody in preparation of preventive and therapeutic antibody drugs, and belongs to the technical field of medicines. The chikungunya virus envelope protein E2 expressed by human embryo kidney 293 cells is used as an antigen to immunize a rabbit, B cells capable of being specifically combined with the chikungunya virus envelope protein E2 are screened from rabbit spleen cells through flow sorting, and signal peptide and variable region gene fragments of an antibody are cloned through reverse transcription-polymerase chain reaction. According to the present invention, the chikungunya virus-resistant monoclonal antibody with high neutralizing activity and capable of 100% protection of mice against chikungunya virus lethal attack is obtained by carrying out enzyme-linked immunosorbent assay, in-vitro virus neutralization and mouse toxicity attack experiment after mammalian cell expression and purification, and the recombinant chikungunya virus-resistant monoclonal antibody has characteristics of high neutralizing activity and high immunogenicity, and can be used for preparing the chikungunya virus-resistant monoclonal antibody, and the recombinant chikungunya virus-resistant monoclonal antibody. The monoclonal antibody has application value in prevention and treatment of yellow fever.

The invention belongs to the technical field of biology, and particularly discloses a cell line capable of stably expressing an nsP4 gene and application of the cell line in preparation of a replication-deficient chikungunya virus. The inventor uses retrovirus for expressing CHIKV nsP4 to infect hamster kidney cells (hamster kidney cells), after puromycin screening, verification of passage stability of monoclonal cells, protein expression stability, replication-deficient virus titer and the like is carried out, finally, a cell line which can be used for continuous passage of CHIKV replication-deficient viruses and has high titer is obtained, and the preservation number is CCTCC NO: C2025281. The replication-deficient virus CHIKV-delta nsP4 generated by the RNA of the nsP4 gene deleted from the trans-complementary CHIKV of the cell line has good safety, immunogenicity and immune protection efficacy, can effectively resist the challenge infection of wild viruses, and can be used for preparing a safe and effective CHIKV novel vaccine candidate strain.

The invention provides a chikungunya virus invasion model, an establishment method and application, according to the invasion model, chikungunya structural protein expression plasmids and firefly luciferase reporter gene plasmids containing specific packaging signals are co-transfected to mammalian cells, and the chikungunya structural protein expression plasmids and the firefly luciferase reporter gene plasmids containing the specific packaging signals are co-transfected by utilizing a packaging mechanism of the packaging signals. And self-assembling to form the high-simulation virus-like particle capable of efficiently bearing the reporter gene. According to the method, evaluation of chikungunya virus invading cells without depending on a BSL-3 experimental environment is achieved, and drugs / vaccines for resisting the chikungunya virus can be quantitatively screened through firefly luciferase. The method has the advantages that the whole process that viruses invade host cells can be efficiently and accurately simulated, meanwhile, high sensitivity and operation convenience are achieved, and a stable, reliable and high-drug-effect-resolution experimental platform is provided for deeply researching the invasion mechanism of CHIKV and developing targeted inhibitor high-throughput screening.

The present invention relates to a multiplex and simultaneous antigen detection kit (200) for the rapid diagnosis of Dengue, Chikungunya, and two forms of Malaria (Plasmodium vivax and Plasmodium falciparum) from whole blood samples. Utilizing vertical flow technology, the kit allows the detection of multiple antigens concurrently, offering faster results with enhanced sensitivity and specificity compared to traditional lateral flow assays. The diagnostic device employs metal nanoparticles and gold conjugates to detect the specific antigens, facilitating co-infection detection without the need for serum or plasma separation.

The present invention is related to novel liquid and lyophilized formulations of Chikungunya virus useful as vaccines and methods for their preparation.

The invention features compositions and methods for the prevention or treatment of one or more strains of Chikungunya virus, as well as other alphavirus-mediated diseases.

The invention provides a kit and a method for detecting chikungunya virus, the kit comprises a primer composition, and the primer composition comprises an external primer pair, an internal primer pair and an annular primer pair. The external primer pair comprises a forward external primer and a reverse external primer, the internal primer pair comprises a forward internal primer and a reverse internal primer, and the annular primer pair comprises a forward annular primer and a reverse annular primer. The invention also provides a kit and a method for multiple detection of Chikungunya virus and Zika virus, so as to achieve rapid and reliable nucleic acid detection.

The invention relates to the technical field of medicinal chemistry, in particular to a nucleoside derivative and preparation and application thereof, the nucleoside derivative has good antiviral activity, and viruses include but not limited to dengue virus, chikungunya virus, coronavirus and influenza virus. The nucleoside derivative overcomes the defects that a traditional oral preparation is poor in absorption and can only be administrated through injection, has high oral bioavailability, can inhibit the degradation of EETs into DHEAT, can be used for inhibiting an NF-kappa B signal channel, improving the vascular function, relieving oxidative stress and adjusting inflammation balance, and can be used for preventing and treating diseases such as inflammatory diseases. The nucleoside derivative shows lower gastrointestinal adverse reaction than that of a non-steroidal anti-inflammatory drug, the double-target compound formed by introducing an sEH inhibitor into GS-441524 shows excellent effects in the aspects of in-vitro and in-vivo anti-DENV-2 activity and pharmacokinetic performance in the candidate compound screening experiment process, shows an inhibition effect on multiple viruses, and can be used for preparing anti-DENV-2 drugs. And a wider choice is provided for antiviral treatment medicaments.

The invention relates to the field of biological detection, in particular to a primer probe set, a detection reagent and application of the primer probe set and the detection reagent in detection of virulent pathogens. The invention provides a primer probe group. Comprising the following steps: amplifying lasa fever virus, Xinjiang hemorrhagic fever virus, Zaire Ebola virus, Chikungunya virus, monkey pox virus, eastern equine encephalitis virus and tick-borne encephalitis virus; and the primer probe group is used for amplifying the Venezuela equine encephalitis virus and the Rift Valley fever virus. The kit is in a freeze-dried solid state and can be transported and stored at normal temperature. The kit is good in sample compatibility, the matched sample lysate can directly expand the sample, nucleic acid purification is not needed, nine virulent pathogens can be simultaneously detected in a one-tube reaction system, rapid screening of large-batch samples is achieved, the whole-process detection is within 1 h, and the result is accurate and reliable.

The invention provides a monoclonal antibody aiming at chikungunya virus (CHIKV) or an antigen binding fragment of the monoclonal antibody, a related product of the monoclonal antibody, and a preparation method and application of the monoclonal antibody and the related product. The monoclonal antibody or the antigen binding fragment of the monoclonal antibody can be specifically bound with CHIKV E protein with high affinity and has high neutralizing activity on CHIKV viruses, and therefore the monoclonal antibody or the antigen binding fragment of the monoclonal antibody has great potential in development of CHIKV virus antigen detection kits and research and development of CHIKV prevention or treatment antibodies, and has good application prospects. The kit shows a remarkable application prospect in the fields of clinical detection, prevention and treatment of CHIKV, and has an extremely high application value.

The invention provides a chikungunya virus whole genome sequencing and typing kit. The kit comprises a multiple PCR primer pool and a library construction reagent. The primer pool can cover the full length of a CHIKV genome, the length of an amplified fragment is 100-270 bp, and it is ensured that multiple genotypes such as AL, ECSA, IOL and WA all have amplification compatibility. The kit can be adapted to two sequencing platforms, namely Illumina and Huadao MGI, for library building and sequencing, so that the transferability of a cross-laboratory is ensured. The kit is suitable for clinical samples, mosquito-borne samples and environmental samples of which the Ct is less than or equal to 30, and is wide in application scene. The kit has good adaptability to strains of different genotypes, and can be widely applied to scientific research, monitoring and traceability analysis.

This disclosure provides methods and compositions relating to the characterization of the chikungunya virus genome, including specific sets of oligonucleotide primers for the amplification of the chikungunya virus genome for downstream sequencing, alignment, and identification of variants in the chikungunya virus genome.

The present disclosure provides a method, system and medium for intelligent typing of chikungunya virus, obtains CHIKV sequence data from a public database, performs quality control, uses an artificial intelligence model to extract typing reference sequences of CHIKV, and then compares the sequence data with the typing reference sequences one by one. If the comparison result of the sequence data and a certain typing reference sequence is similarity>99% and sequence coverage>99%, the sequence information of the typing reference sequence is supplemented to the sequence data, and a typing sequence database is generated. The present disclosure uses an artificial intelligence model to realize automatic extraction, semantic alignment and standardization of multi-source data, solves the bottleneck of data dispersion and metadata loss, realizes intelligent typing of chikungunya virus, encapsulates complex bioinformatics processes into a "one-key" online tool, significantly reduces the technical threshold, enables grassroots personnel to independently complete high-level analysis, and provides real-time, visual molecular evidence and risk prompts for epidemic prevention and control.

The present disclosure provides, for example, uses of compounds such as a compound of Formula (I) in the treatment of viral infections, for example, viral infections caused by one or more of a Kitrinoviricota virus and a Negarnaviricota virus (e.g., Marburg virus, influenza virus, Lassa virus, chikungunya virus, dengue virus, Zika virus, respiratory syncytial virus or combinations thereof), in a subject in need thereof.

The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.